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ABSTRACT 
 
Mutations of OCRL1 are associated with both the oculocerebrorenal syndrome Lowe, 
a multi-systemic and Dent-2 disease, a renal tubulopathy. We have identified a mutation in 
130 Lowe syndrome families and 6 affected by Dent-2 disease with 51 of these mutations 
being novel. No founding effect was evidenced for recurrent mutations. Two mutations 
initially reported as causing Dent-2 disease were identified in patients, including two brothers, 
presenting with Lowe syndrome thus extending the clinical variability of OCRL1 mutations.  
mRNA levels, protein content and PiP2-ase activities were analyzed in patient’s 
fibroblasts. Although mRNA levels were normal in cells harbouring a missense mutation, the 
OCRL1 content was markedly lowered suggesting that enzymatic deficiency resulted mainly 
from protein degradation rather than a catalytic inactivation as usually reported. Analysis of a 
splicing mutation that led to the elimination of the initiation codon evidenced the presence of 
shortened forms of OCRL1 that might result from the use of alternative initiation codons. The 
specific mapping of the frameshift and nonsense mutations, exclusively identified in exons 1-
7 and exons 8-23 respectively for Dent disease and Lowe syndrome together with the possible 
use of alternative initiation codons might be related to their clinical expression i.e. Lowe 
syndrome or Dent-2 disease. 
  
 
KEYWORDS : 
OCRL1 – Lowe syndrome – Dent 2 disease – Phosphatidylinositol 4,5 biphosphate  
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INTRODUCTION 
 
Lowe syndrome 
 The oculocerebrorenal syndrome of Lowe (OCRL [MIM#309000]) is a rare X-linked 
multisystem disorder presenting with major abnormalities in the eyes, the kidneys and the 
central nervous system [Lowe et al., 1952; Loi, 2006].  OCRL is a rare disease with a 
prevalence estimated between 1 and 2 boys per million people. Ocular abnormalities include a 
constant prenatal development of cataracts and frequent associated signs such as glaucoma, 
microphthalmos, decreased visual acuity and corneal keloid formation. Neonatal hypotonia, 
intellectual impairment and areflexia are also cardinal features. The majority of patients have 
a cognitive delay and behavioural troubles including temper tantrums and aggressiveness are 
frequently noted. Brain magnetic resonance imaging (MRI) may show periventricular cystic 
lesions [Schneider et al., 2001; Loi, 2006]. Fanconi syndrome, a generalized impairment of 
the proximal tubular cells functions, is a major feature.  
Onset of the tubular dysfunction can vary between patients and the severity tends to worsen 
with age. Low molecular weight proteinuria (LWMP) is invariably present and 
aminoaciduria, hypercalciuria and bicarbonaturia are frequently included. Progressive 
glomerular dysfunction leads usually to renal failure. Skeletal muscle abnormalities may 
develop as secondary consequences of hypotonia or renal dysfunction. Nontender joint 
swelling and subcutaneous nodules are also frequently described in affected patients and may 
reflect a primary abnormality of connective tissue growth. Lowe syndrome results from 
mutations of the OCRL1 gene (MIM #300535) that encodes a phosphatidyl inositol 4,5 
biphosphate (PI(4,5)P2) phosphatase.  
 
Dent disease 
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 Dent's disease (Dent-1, MIM#300009), is a X-linked proximal renal tubulopathy, 
characterized by LWMP, hypercalciuria and progressive renal insufficiency. In addition, other 
features of proximal tubular dysfunction such as glycosuria, aminoaciduria, phosphaturia, 
uricosuria or complete Fanconi syndrome may also be present [Dent and Friedman, 1964; 
Thakker, 2000]. Except for rickets noted in some patients; no extra-renal manifestations of the 
disease have been reported. 
  Mutations in the CLCN5 gene (MIM #300008) encoding the renal voltage-
gated chloride channel CLC-5 have been reported in 60% of patients with Dent's disease 
[Lloyd et al., 1996, Hoopes et al., 2004]. ClC-5 is mainly localized in subapical endosomes of 
epithelial kidney cells and contributes to the acidification of intra-endosomal compartments 
and participates in membrane recycling in the proximal tubule [Devuyst et al., 1999; Piwon et 
al., 2000]. A recent study showed that mutations in the OCRL1 gene can lead to a Dent-like 
phenotype (Dent-2 disease, DD-2, MIM #300555) that can present as a clinical intermediate 
between Lowe syndrome and Dent disease [Hoopes et al., 2005; Bökenkamp et al., 2009].     
Nevertheless, DD-2 patients harbouring an OCRL1 mutation displayed comparable decrease 
in PI(4,5)P2ase activity and OCRL1 content to those reported for patients affected by Lowe 
syndrome [Hoopes et al., 2005; this study]. 
 
OCRL1  
 
 OCRL1 is a type II inositol polyphosphate 5-phosphatase that participates into the 
Lowe, 2005]. OCRL1 has been originally localized to the Trans-Golgi Network and to 
lysosomes [Olivos-Glander et al., 1995;  Dressman et al., 2000; Ungewickell et al., 2004] and 
more recently to endosomes [Choudury et al., 2005; Hyvola et al., 2006; Erdmann et al., 
2007]. Abnormalities in the actin cytoskeleton have been demonstrated in Lowe fibroblasts 
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[Suchy and Nussbaum, 2002] and OCRL1 was recently proposed to play a role in regulating 
membrane trafficking and actin dynamics  [Lowe, 2005; Faucherre et al, 2005]. 
 The OCRL1 gene spans 52278 bp on chromosome Xq24.26 [ENSG00000122126] and 
contains 24 exons with exon 18a as an alternatively spliced exon mostly expressed in brain 
[Attree et al., 1992; Nussbaum et al., 1997]. The ATG start codon was initially assigned to 
exon 2 [Attree et al, 1992], however recent reports mapped the initiation codon in exon 1 
[Hyvola et al., 2006; Erdmann et al, 2007; Mao et al., 2009]. Accordingly the 5156 bp cDNA 
(NM_000276) encodes a protein monomer of 901 amino-acids (MW = 103 226 kDa).  
 
 This paper reports 51 novel mutations of the OCRL1 gene associated either with Lowe 
syndrome or Dent-2. Correlations between the mutations and their expression at the mRNA, 
functional and protein levels will be discussed in regard to their clinical expression. Based on 
these data, putative mechanisms to explain how mutations of the OCRL1 protein express as 
heterogeneous clinical entities will be discussed. 
 
MATERIAL AND METHODS 
 
Patients and samples 
 A panel of 175 non-related families addressed to the laboratory for suspicion of Lowe 
syndrome has been investigated. Among the male patients addressed for suspicion of Lowe 
syndrome, 124 index cases presented with full criteria of Lowe syndrome. 15 mothers of 
deceased children likely to be affected by Lowe syndrome were also investigated for 
mutations in the OCRL1 gene. French clinical centres addressed 58% of the families with the 
remaining families originating from Europe (18%), Middle-East (5%), North-America (5%), 
Asia (6%) and Australia (3%).   
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 41 patients affected by Dent's disease were additionally included in the study. All 
patients originated from France, they did not show cataract or noticed neurological troubles 
and did not harbour mutations in the CLCN5 gene.   
 Blood samples and, whenever possible, fibroblasts, were obtained from the affected 
patients and/or from their relatives. An informed consent allowing genetic studies was 
obtained from all patients included in the study.   
 
Mutation detection 
Genomic DNA was isolated using standard procedures. The 24 exons of the OCRL1 
gene were amplified from genomic DNA as described previously [Monnier et al., 2000]. For 
mutational analysis, PCR-amplified DNA products were subjected to direct automated 
sequencing on an ABI 3130 DNA Analyser (Life Technologies, Carlsbad, CA, USA). 
Alternatively RNA was extracted from 2-5 106 fibroblast cells using the Trizol 
reagent (Life Technologies, Carlsbad, CA, USA).  RNA was dissolved in 50 µl of RNAse-
free water. Reverse transcription was performed by using 0.2 mg of total RNA at 48°c for 60 
minutes with 50 U of Expand Reverse Transcriptase (Roche, Basel, Switzerland) and in the 
presence of oligo-dT and the following specific primer (5'-
AACTTTGGCTTGGCAATATAAGTC). The resulting cDNA was then amplified and 
sequenced as previously described.24 Mutations responsible for aberrant sized transcripts were 
characterized by direct sequencing of the corresponding exon and intron-exon junctions.  
Mutation assignment was based on the cDNA sequence (Genbank # NM_000276) 
using the first coding ATG of exon 1 as initiation codon according to international guidelines 
for description of sequences variants (http://www.hgvs.org/mutnomen). This resulted in an in 
frame addition of 51 nucleotides at the 5' end of the cDNA and of 17 amino acids at the N 
terminal end of the protein in comparison with the initial nomenclature [Attree et al., 1992]. 
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None of the novel variants identified in this study were found after screening of 200 
chromosomes from the general population. Genomic rearrangements were evidenced using 
data obtained from PCR screening or MLPA analysis in probands. In families harbouring a 
genomic rearrangement, the carrier status of mothers was determined using a homemade 
MLPA assay (MRC Holland, Amsterdam, The Netherlands) [Coutton et al, 2010].  
 
Quantitative transcript analysis 
 Quantitative PCR was performed using 100 ng of cDNA in a final volume of 25 µl 
and specific primers for the OCRL1 gene (F-5'-CGAGCTGTATCAGCGATGTC; R-5'-
GGAGGCCTCAGGAGAAGACT) and the GAPDH gene used as control (F-5'-
CATCAAGAAGGTGGTGAAGC; R-5'- GAGCTTGACAAAGTGGTCGT). The OCRL1 
primers allowed the amplification of a 197 bp fragment spanning exon 21 to 23. Duplicated 
samples were PCR were run on a iQ Cycler apparatus in presence of the iQ SYBR Green 
Supermix containing 500 nM primers (Biorad, Hercules, CA, USA). 
 
Enzymatic assay for PI(4,5)P2 phosphatase activity 
 Activity was assayed as described previously on cell extracts prepared by freeze-
thawing of fibroblasts obtained from affected and non affected patients except that each assay 
included 50 µg of fibroblast protein and that quantification was performed by direct analysis 
of the TLC plates using a Beta Imager 2000 (Biospace, Paris, France) [Suchy et al., 1995; 
Satre et al., 1999].  
 
Western blot analysis 
 For western blot analysis, aliquots of cell extracts (25 µg of protein) were resolved by 
an 8% SDS-polyacrylamide gel electrophoresis and electro-blotted onto Immobilon P transfer 
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membrane (Millipore, Billerica, MA, USA). OCRL1 was revealed using polyclonal 
antibodies raised in rabbit against the N-terminal region (amino-acids 18-217) and a 
peroxidase-labelled mouse anti-rabbit detection system. As control we used the signals 
obtained using polyclonal antibodies raised against the β-subunit of the mitochondrial 
ATPase. The amount of OCRL1 present in each sample was determined by quantitative 
western blot analysis using a ChemiDoc XRS apparatus and the Quantity One software 
(BioRad, Hercules, CA, USA), after correction of protein loading by Coomassie blue staining. 
 
Results 
Mutation analysis 
 We have identified a mutation in the OCRL1 gene in 130 out of the 175 families 
included for Lowe's syndrome and in 6 out of the 41 Dent disease families. 51 of these 
mutations were novel (Table 1) with four of them identified in patients affected by Dent-2 
disease. Extensive genomic and cDNA sequencing analysis led to the correction of 
boundaries of exons 8, 9, 11, 12, 13, 14 in reference to those reported in the Lowe Syndrome 
Mutation Database28 and to the use of a cDNA numbering based on the use of initiation codon 
in exon 1 (Supplementary Table S1). 
 Near to 200 mutations have been identified so far in the OCRL1 gene in association 
with Lowe syndrome or Dent-2 disease (Supplementary Table S2). Frameshift, splicing or 
non-sense mutations leading to a premature termination of the protein represented 63% of the 
mutations whereas missense mutations and genomic deletion accounted respectively for 33% 
and 4% of the molecular variations. No noticeable differences in this distribution were noticed 
when comparing Lowe syndrome or Dent-2 Disease. 33 recurrent mutations were identified 
and accounted for the disease in 41% of the genotyped families. 17 mutations have been 
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reported in more than 3 families (n=3: p.Ile274Thr, p.Arg318Cys, p.Arg334Stop, 
p.Gln388Stop, p.Arg822Stop; n=4: c.940-11G>A, p.Gly421Glu, p.Arg500Stop, 
p.Arg541Stop, c.1694_1695insCCTT, c.2360_2361delTG, p.Arg844Stop; n=5: 
p.Arg663Stop, p.Arg695Stop , p.Arg810Stop; n=8: p.Arg500Gln; n=10: c.2581G>A). As it 
could be inferred from data presented in supplementary Table S2, none of these mutations 
appeared to be population specific.  
 Genetic investigation of 98 mothers of patients affected by Lowe syndrome showed 
the occurrence of a de novo mutation in 36 cases (37.2 %) whereas 3 cases of mosaicism were 
characterized in our panel of genotyped families indicating that, although not frequent, 
mosaicism must be taken in account for genetic counselling. 
 As shown in Figure 1, 53 out of the 66 missense mutations reported to date mapped to 
the PI(4,5)P2 phosphatase domain spanning exons 9-15. They involved amino-acids defined 
as major determinants for specificity of the inositol polyphosphate 5-phosphatase activity 
[Whisstock et al., 2000; Tsujishita et al., 2001]. The remaining missense mutations were 
identified in the C-terminal ASH-RhoGAP-like domain spanning exons 16 to 23 [Peck et al., 
2002; Faucherre et al., 2003, Choudhury et al., 2005; Hyvola et al., 2006; Erdmann et al., 
2007] and involved amino acids located in well conserved domains (supplementary Figure 
S1). Noticeably, no missense mutations have been identified so far in exons 1 to 8.  
 Frameshift mutations or nonsense mutations leading to premature termination of the 
protein have been characterized in all exons but exons 2 and 3 (Fig 1). While nine 
substitutions affected directly the consensus acceptor or donor sites at the exon-intron 
junctions, seven additional intronic mutations induced abnormal splicing: c.40-14A>G, 
c.238+4701G>A, c.940-11G>A, c.1467-3C>G, c.1879+5G>A, c.1880-5del16, 
c.2469+2_6delinsA, c.2581+4A>G. Transcript analysis showed that 3 substitutions affecting 
the last nucleotide of exons 9, 14 and 22: c.824G>C, c.1466G>A, c.2581G>A affected the 
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splicing. Thus, the p.Gly275Ala, p.Ser489Asn, p.Ala861Thr mutations, initially reported as 
missense mutations [Kawano et al., 1998; Monnier et al., 2000] led thus primarily to a 
premature termination of the protein.  
 Noticeably, while frameshift and nonsense mutations associated with Lowe syndrome 
concentrated in exons exons 8 to 23, all frameshift and nonsense mutations causative of Dent 
2 disease have been characterized so far only in the first seven exons.  
 
Functional expression of mutations 
mRNA expression  
 
 As shown in Figure 2 no significant differences in the level of mRNA expression of 
the OCRL1 gene could be evidenced in patients harbouring a missense mutation when 
compared to controls. At difference, patients harbouring stop, frameshift or splicing mutations 
showed a very low mRNA content that indicated either a decreased transcription or more 
likely a mRNA instability resulting from a non sense mediated decay mechanism. No 
difference was observed between patients affected by Lowe syndrome or Dent-2 disease. 
Noticeably, one patient harbouring a c.[40-14A>G] splicing mutation showed a normal 
amount of mRNA (Figure 2, arrow). As shown in panel A of the figure 3, the c.40-14A>G 
mutation resulted in the production of two abnormal transcripts. Sequencing analysis showed 
that whereas both transcripts could be amplified and quantified, they both lacked the 3' end of 
exon 1 that contains the ATG initiation codon (supplementary Fig S2).  
 
PIP2ase activity 
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PI (4,5)P2 phosphatase activity was measured in 12 patients harbouring a missense 
mutation and in 11 patients harbouring a nonsense or a frameshift mutation that led to a 
premature termination of the protein. As presented in table 2 the enzymatic activities 
measured in patients with either a missense mutation or a mutation leading to a premature 
termination of the protein showed a mean inhibition of 85-90% when compared to PI (4,5)P2 
phosphatase activity determined in fibroblasts originating either from healthy individuals or 
from patients addressed for a suspicion of Lowe syndrome and for whom no mutation had 
been identified in the OCRL1 gene. No significant differences between the residual activities 
measured in fibroblasts harbouring a missense mutation and those harbouring a nonsense or 
frameshift mutation were evidenced. Likewise no differences of PI (4,5)P2 phosphatase 
activities could be evidenced between Lowe syndrome or Dent-2 patients (not shown). 
Residual activities measured in mutant fibroblasts were likely to correspond to non specific 
hydrolysis of PI (4,5)P2  by other inositol polyphosphate phosphatases present in fibroblasts 
since they were also determined in cells fully devoid of OCRL1 as a consequence of a 
genomic deletion of the OCRL1 gene [Lin et al., 1997; Monnier et al., 2000; this paper].  
 
OCRL1 protein analysis 
 The amount of OCRL1 was estimated in total cell extracts using either the total 
protein amount or the β-ATPase signals for normalisation. As shown in Figure 4, patients 
harbouring a missense mutation in the OCRL1 gene (lanes 2-6) had a markedly reduced 
content of OCRL1 when compared to controls (lanes 1, 7, 8, 12). Two bands were revealed 
by antibodies, the upper band at ≈ 105 kDa corresponds to the native OCRL1 while the lower 
band at ≈ 75 kDa corresponds to a proteolytic product [Lichter-Konecki et al., 2006]. As 
expected, cells harbouring stop and frameshift mutations and characterized by a low mRNA 
content showed an almost complete absence of OCRL1 (lanes 9,10,11). For quantification 
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studies of OCRL1 presented in table 3, both bands were taken in account. Unexpectedly, most 
missense mutations resulted in a drastic decrease of the OCRL1 content although their mRNA 
content was unaffected (Fig 2). The decrease in OCRL1 was observed whether missense 
mutation mapped to the central phosphatase domain or to the C-terminal Rho-Gap domain 
(Fig 4).  This indicated that missense mutations not only could affect the catalytic properties 
of OCRL1 but also could affect the stability of the protein. Noticeably, expression of the c.40-
14A>G resulted in the presence of a protein doublet at ≈ 80 kDa with no detectable bands at 
100 or 75kDa  (Fig 3, panel B, lane 2).  
 
Clinical expression of mutations 
 All but two of the 124 male patients that presented with classical features of the 
disease i.e. congenital bilateral cataract, central nervous system symptoms and kidney 
troubles harboured a mutation in the OCRL1 gene. However as no cDNA analysis could be 
performed for these two patients, we cannot exclude the presence of a mutation not detected 
by genomic sequencing. At contrast, no mutation in the OCRL1 gene was identified in the 36 
additional male patients presenting with an incomplete panel of oculocerebrorenal symptoms 
although highly suggestive of Lowe syndrome. When tested PI(4,5)P2 phosphatase activity 
also excluded the diagnosis of Lowe syndrome in these patients. 
6 out of the 41 patients included on the basis of diagnosis of a Dent disease not 
associated to the CLC5 gene carried a mutation of the OCRL1 gene. None of these 6 patients 
had ocular or CNS symptoms. 
 A few mutations that mapped to the same amino acid or to amino acids located at 
close vicinity were identified in patients addressed either for diagnosis of Lowe syndrome or 
Dent disease (Table 4). The p.Ile274Thr initially described in a patient presenting with the 
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phenotype of Dent disease [Utsch et al., 2006] was identified in two families, one presenting 
with a classical Dent disease and one diagnosed as a Lowe syndrome family in which the two 
affected brothers had mental retardation and developmental with one of them having a 
congenital cataract. Likewise, the p.Arg318Cys mutation previously reported in 2 families 
with Dent disease [Hoopes et al., 2005; Sekine et al., 2007] was identified in a patient 
presenting with Dent disease and in another patient initially diagnosed as Lowe syndrome 
patient on the basis of renal and CNS symptoms although ocular symptoms at 24 y of age 
were restricted to a severe myopia. Three mutations mapped to amino acids closely located in 
the Rho-GAP domain i.e. p.Ala797Pro, p.Pro799Leu and p.Pro801Leu. While all the three 
mutations were associated with proximal tubulopathy, only two of them (p.Ala797Pro and 
p.Pro801Leu) were associated with congenital cataract and SNC symptoms, typical features 
of the Lowe syndrome. 
 
CONCLUSIONS AND DISCUSSION 
 A major consequence of mutations affecting the OCRL1 gene was the loss of 
PI(4,5)P2ase activity regardless of the Lowe or Dent-2 clinical phenotypes associated with 
mutations in patients and regardless of the pathogenic mechanisms. 
Nonsense mutations, genomic deletions, frameshift or splicing mutations leading to 
the occurrence of a premature termination codon represent 2/3 of the OCRL1 mutations 
identified to date. Expression studies of these mutations indicated that all but one of the 
mutations tested resulted in an almost complete absence of mRNA and protein (Fig. 2 and 
table 3).  
 Interestingly, the splicing c.40-14G>A mutation allowed an apparently normal 
quantitative production of mRNA. However and as shown in Fig. 3 (panel A) the mutation led 
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to the synthesis of two abnormal transcripts lacking the normal initiation codon in exon 1 (see 
supplementary Fig. S2). As shown in panel B of Fig. 3 two peptides with a molecular weight 
close to 80 kDa were evidenced in fibroblasts harbouring the c.40-14 A>G mutation. Based 
on bioinformatics analyses, it has been recently proposed that a differential splicing of the 
OCRL1 gene associated with the possible use of an alternative initiation of translation in exon 
8 that would allow the synthesis of a shortened OCRL1 might occur in different tissues and at 
different developmental stages [Schrimpton et al., 2009]. Remarkably, frameshift and 
nonsense mutations associated so far with Dent-2 disease were exclusively identified in the 
first 7 exons of the OCRL1 gene while all frameshift and nonsense mutations causing Lowe 
syndrome mapped to exons 8-23 (Fig 1). There are only three methionyl residues in the 
sequence spanning exon 3 to 10 at position 158, 187 and 206, respectively in exons 7 and 8, 
that will keep the OCRL1 reading frame. As suggested by Schrimpton [Schrimpton et al., 
2009], use of these methionyl residues as alternative initiation codons  will allow the 
synthesis of 85.425 kDa, 82.159 kDa and 79.976 kDa  peptides respectively, molecular 
weights compatibles with the observed bands at ≈ 80kDa in Fig 3. Such proteins will lack the 
PH domain and a major clathrin binding site [Mao et al., 2009] and are likely to display 
modified interactions with membranes and other proteins. 
 While most missense mutations mapped to the phosphatase domain of OCRL1 
spanning exons 9-15, 14 missense mutations or in-frame deletion have been identified in the 
C-terminal ASH (ASPM, SPD-2, Hydin)-RhoGAP-like domain spanning exons 16 to 23 (Fig 
1). Eight mutations mapped to the ASH/Rab binding domain spanning exons 17-19 (amino 
acids 539-752) close to residues that have been shown to modulate Rab binding and targeting 
of OCRL1 to Golgi and endosomes [Hyvola et al., 2006]. The six missense mutations in 
exons 20-23 affected amino acids that mapped to a region in close interaction with the ASH 
domain [Erdman et al., 2007]. Mutations in exon 21 clustered to a domain showing significant 
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homologies with GAP related proteins (Supplementary Fig S1). Although interaction with 
Rac 1 a member of the Rho family has been reported [Erdman et al., 2007] and low Rac GAP 
activity measured in vitro [Faucherre et al., 2003], whether OCRL1 functions as a GAP in 
vivo is still debated [Lowe, 2005]. Expression studies of the p.I768N and p.A797P mutations 
in COS7 cells suggested that the Rho-GAP like domain is important for the enzymatic 
activity of OCRL1 while being catalytically inactive by itself and showed that this domain 
could also interact with small G-proteins of the Arf family [Lichter-Konecki et al., 2006]. 
Therefore and as suggested by their effect on activity and OCRL1 content, these last two 
residues might play a critical role for the folding of the protein. The ASH-RhoGAP-like 
domain has been recently shown to interact with the Rab5 effector APPL1  [Erdmann et al., 
2007; McCrea et al., 2008] and with Ses1 and Ses2, two closely related endocytic proteins 
[Swan et al., 2010]. Isothermal titration calorimetry studies performed using peptides 
corresponding to the interacting domains of Ses1 and APPL1 with OCRL1 suggested that 
binding of Ses and APPL1 are mutually exclusive and abolished by the same mutations at 
positions 591, 634, 799, 801 in the ASH-RhoGAP-like domain that also disrupt APPL1 
binding. This suggested that Lowe syndrome and Dent disease might result from 
perturbations at multiple sites within the endocytic pathway [Swan et al., 2010]. Noticeably, 
most variants affected amino acids conserved among OCRL1 species and INPP5B but much 
less conserved among other polyphosphate phosphatases. This may suggest that interaction 
with Rab proteins is a specific feature of OCRL1 and INPP5B. 
 The decrease of the PI(4,5)P2ase activity in mutant cells harbouring a missense 
mutation was usually associated with a deleterious effect of the missense mutations on 
phosphatase activity, whether they mapped to the catalytic PI(4,5)P2ase domain or to the Rho-
GAP domain [Lin et al., 1997., Hyvola et al., 2006., Schrimpton et al., 2009]. However and as 
illustrated in Fig. 4 and Table 3, the consequence of missense mutations is mostly a decrease 
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of the amount of OCRL1 present in the cell. This is likely to result from an abnormal 
processing of the protein since OCRL1 mRNA levels were normal in the cells harbouring 
these missense mutations (Fig. 2). The protein degradation might be the consequence of the 
activation of endoplasmic reticulum-associated degradation (ERAD) or of tunfolded protein 
response (UPR) as an answer to the accumulation of unfolded or misfolded mutant OCRL1 in 
the endoplasmic reticulum [Schröder and Kaufman., 2005]. Conclusions of functional studies 
based on expression mutant OCRL1 in cellular models must thus take in account protein 
degradation processes when analysing the physiological relevance of the different mutations. 
Nevertheless, a small amount (20-30%) of OCRL1 was detected in a few mutant cells 
although PI(4,5)P2ase activity was almost totally absent. In these situations, the overall 
decrease of PI(4,5)P2ase activity is likely to result from two processes: a decrease of the 
amount of OCRL1 through protein degradation and a catalytic inactivation. A few missense 
mutations e.g. p.Phe242Ser, p.Ala797Pro resulted in the presence of both a small amount of 
protein and a residual PiP2ase activity. Noticeably, although the Lowe patients harbouring 
these mutations presented with classical eye and kidney features, their neurological symptoms 
were less severe and their degree of mental retardation was moderate. This may reflect a 
differential dependence of tissues or of developmental stages toward PI(4,5)P2 homeostasis. 
Differences in clinical expression that were observed between patients harbouring different 
mutations might thus reflect variability in protein synthesis and/or catalytic properties in the 
different tissues depending on the nature of the mutation beside variability of the individual 
genetic background.  
 Mutations of the OCRL1 gene have been associated with two distinct clinical 
phenotypes i.e. Lowe syndrome and Dent disease. Although apparently undistinguishable 
from the Dent phenotype associated to the CLCN5 gene, Dent phenotype associated with 
OCRL1 mutations has been referred as Dent-2 disease to specify the genetic cause of the 
Page 16 of 46
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
  17 
disease and may represent a mild variant of Lowe syndrome [Bökenkamp et al., 2009]. 
Accordingly, it has been proposed that a phenotypic continuum exists between Dent-2 disease 
and Lowe syndrome. This continuum was not only observed between patients harbouring 
different OCRL1 mutations but also occurred between patients harbouring the same mutation 
as presented in table 4. Clinical phenotypes range from patients affected by severe Lowe 
syndrome with typical ocular, neurological and renal features to Dent-2 patients presenting 
only with renal impairment and comprise atypical forms of Lowe syndrome presenting with 
incomplete eye symptoms or moderate neurological troubles. Presence of a residual 
PI(4,5)P2ase activity has been documented during this study in patients presenting usually 
with a moderate clinical expression. However, it must be noted that ocular and neurological 
symptoms were documented even in Lowe patients showing a residual PI(4,5)P2ase activity 
up to 20% of the normal values in their fibroblasts. On the other hand, it must be kept in mind 
that mild and severe presentations of Lowe syndrome together with pure real forms of Dent 
disease were associated with a complete loss of the OCRL1 enzymatic activity. A possible 
explanation of this clinical variability might be the presence of modifying factors 
(compensatory phosphatases, interacting proteins…) whose expression will depend on the 
genetic background of the different patients. The main clinical difference observed between 
two brothers presenting with a Lowe syndrome and harbouring the same p.Ile274Thr 
mutation e.g. a documented unilateral cataract for the youngest and no signs of cataract for 
the eldest one would thus likely result from such modifying factors. Along this line we have 
investigated a possible role of INPP5B, a phosphatase. No significant variations in the 
INPP5B content could be evidenced when comparing fibroblast extracts originating from 
healthy controls or patients affected either by Lowe syndrome or Dent-2 disease. This was in 
agreement with our data showing that no significant differences of the PiP2-ase activity could 
be evidenced between Lowe syndrome and Dent-2 disease patients (table 2). 
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The report of truncated forms of OCRL1 that might result from the use of alternative 
initiation codons open also new perspectives to explain clinical variability associated with 
OCRL1 mutations. However these investigations were performed on skin fibroblasts and 
using antibodies that may not recognize all forms of truncated or alternatively spliced 
OCRL1. It will be very important to extend these studies to other cell types that are more 
affected by the disease e.g. renal and ocular cells and to use a larger panel of antibodies 
directed against different domains of the protein in order to gain new insights regarding the 
differential pathological mechanisms leading to the different clinical phenotypes.  
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LEGENDS OF FIGURES 
 
Figure 1. Mapping of mutations associated with Lowe syndrome and Dent's disease in the 
OCRL1 gene. 
Exons, including the alternatively spliced exon 18a, are numbered 1 to 23 and are drawn to 
scale at the exception of the non-coding sequence of exon 23.   The catalytic phosphatase 
domain is indicated in black, the PH domain in hatched, the ASH-Rab binding domain in light 
grey, the Rho-GAP like domain as a punctuated pattern and the 5’ and 3' untranslated regions 
are shown in dark grey. LIDIA and LIDLE refer to motives involved in clathrin binding [Mao 
et al., 2009] and FEDNF to amino-acids involved in AP-2 clathrin adaptator binding 
[Ungewickell et al., 2004]. Frameshift and nonsense mutations are indicated using their 
cDNA numbering above the schematic representation of the cDNA while missense mutations 
and in frame deletions are presented below the cDNA and designated by their protein 
numbering. Mutations indicated in bold correspond to nonsense mutations. Stars refer to 
intronic mutations leading to splicing defects. Horizontal bars indicated gross genomic 
deletions.  
 
Figure 2. Quantification of mRNA OCRL1 expression in patients harbouring a mutation of 
the OCRL1 gene. 
OCRL1 and GAPDH mRNAs were isolated from fibroblasts and quantified as described in 
Material and Methods. Horizontal black bar represent the mean and upper and lower boxes 
the 2 SD limits. Arrow points to the ratio value measured in a patient affected by Dent 
Disease and harbouring a c.40-14G>A mutation.  
 
Figure 3. mRNA and protein expression of the c.40-14 A>G mutation. 
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Panel A. cDNA obtained from fibroblasts harbouring the c.40-14A>G mutation was amplified 
using primers allowing amplification of a sequence encompassing exons 1, 2 and 3. 
Amplification products were analyzed using a 2% agarose gel. Amplification of the mutant 
cDNA (lane 1) generated two bands respectively long of 288 and 391 bp (arrows) while 
amplification of the normal sequence (lane 2) generated a 488 bp fragment as expected.  
Panel B. Western blotting of fibroblast extracts was performed as described in Material and 
Methods. Lanes 1, 4: control fibroblasts; lane 2: c.40-14A>G mutant fibroblasts; lane 3: 
p.Ile274Thr mutant fibroblasts. 
 
Figure 4. Western blot analysis of OCRL1 in control and patient fibroblasts.   
Fibroblasts extract (25 µg) prepared as described in Material and Methods was loaded in each 
lane. Upper panel: western blot analysis using polyclonal antibodies directed againts OCRL1. 
Lane M: molecular weight markers, lanes 1, 7, 8, 12 : control patients, lane 2: p.Glu468Gly, 
lane 3: p.Arg318Cys, lane  4: p.Asn373Tyr, lane 5: p.Pro801Cys, lane 6: p.Pro799Leu, lane 
9: p. Arg810Stop, lane 10: c.2469+2T>G, lane 11: c.825-2A>G. Lower panel: protein loading 
in the different lanes was demonstrated by a western blot analysis of the same blot with the 
use of antibody against the β subunit of the mitochondrial ATPase .  
 
Figure S1. Conservation of residues located in the phosphatidyl-inositol phosphatase catalytic 
domain and in the Rab and Rho-GAP domains of OCRL1 and related proteins.  
Amino acids alignment is given with identical residues shown by dashes. Mutated residues 
are shown in bold. Numbering of the amino-acids refer to the human OCRL1 sequence 
(ENSP00000360154). Upper amino acids represent the missense mutations identified in 
patients affected by Lowe syndrome and Dent disease (underlined character). Sequences were 
obtained from SwissProt and Genbank with the following accession number. OCRL1:  H. 
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sapiens Q01968 , M. musculus Q6NVF0, C. elegans NM 060183, D. melanogaster NP 
569962; INPP5B: NP005531; INPPL1: NP001558; SHIP: NP001017915; Synaptojanin: 
NP003886; ARHGAP10: AAI09030; RHOGAP4: NP001657; Oligophrenin: O60890; 
RACGAP1: AAH32754 . 
. 
Figure S2. Schematic representation of the splicing consequences of the c.40-14G>A 
mutation. 
Element involved in the splicing (donor and acceptor sites) of normal and mutant exons 1, 2 
and 3 are indicated in the sequences (bold character). The c.40-14A>G mutation (underlined 
character) revealed a cryptic donor site in exon 1 located in position -82 that was used for 
both mutated transcripts. In mutant transcript #1 splicing used a cryptic acceptor site of intron 
1 at position  -24 while exon 2 was completely skipped in mutant transcript #3. This 
representation was based on sequencing data obtained after cloning of the different transcripts 
that have been evidenced.  
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Patient 
ID 
Exon 
 
 
Nucleotide 
changea 
 
Protein 
changeb 
 
Enzyme 
activityc 
Disease 
status 
Aged Ocular 
symptomse 
 CC      G 
Neurological  
symptomse 
 NH      DD     MR 
Renal symptomse 
 
 FS      PT        RF      AA   LMWP    P       Ca 
05den10 1 c.40-14A>G Splicing defect 1.6 Dent 7 -  -      +  +  
09ls009 i1 c.238+4701A>G Splicing defect  Lowe 7 +   +   +   +   
04ls15 8 c.632delT p.Val211AspfsX38  Lowe 6 + + + + +/-    +  +  
06ls37 8 c.688C>T p.Arg230X  Lowe 2 +  + +   +  +    
05ls26 8 c.702T>G p.Tyr234X  Lowe 1             
02ls42 9 c.725T>C p.Phe242Ser 2.6 Lowe 30 + + + + +  +   +  + 
02ls25f 
02ls26f 
9 
 
c.821T>C 
 
p.Ile274Thr 
 
 Lowe 
Lowe 
43 
34 
- 
+ 
 
 
 
 
+ 
+ 
+/- 
+/- 
  + 
+ 
 + 
+ 
  
08ls008 i9 c.825-2A>G Splicing defect  Lowe 17 +   + +  +   +   
06ls59 10 c.830A>G p.Gln277Arg  Lowe 7 +   + +  +  + + +  
06ls54 
07den01 
11 
 
c.952C>T 
 
p.Arg318Cys 
 
 Lowe 
Dent 
23 
7 
- 
- 
- + + 
- 
+ + + +  
+ 
+ 
+ 
+  
10ls011 11 c.1005C>G p.Tyr335X  Lowe 5 + - + + +  +   + +  
06ls32g 
 
11 
 
c.1009C>T 
c.1082G>T 
p.Arg337Cys 
p.Arg361Ile 
1.4 Lowe 1 +  +       + +  
04den01 12 c.1060A>C p.Asn354His  Dent 27 -  -        +  
98ls44 12 c.1115T>G p.Val372Gly  Lowe 22 + +  +  + +      
06ls15 12 c.1117A>T p.Asn373Tyr 1.4 Lowe 13 +  + + + + +  + +   
98ls48 12 c.1121C>T p.Ser374Phe  Lowe 3 +  + +  + +  + + +  
10ls016f 
10ls017f 
12 
 
c.1241A>G 
 
p.His414Arg 
 
 Lowe 
Lowe 
2 
5 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
   
 
+ 
+ 
+ 
+ 
+ 
+ 
09ls014 13 c.1341_1342delCT p.Leu448GlufsX17  Lowe 1 +  +   +    + +  
03ls38 13 c.1351G>A p.Asp451Asn  Lowe
 
30
 
+ +  +  + +      
00ls37 13 c.1355delA p.Gln452ArgfsX1  Lowe
 
12
 
+   +         
00ls03 14 c.1369C>G p.Arg457Gly 0,6 Lowe
 
20
 
+   + + +       
06ls17 14 c.1378A>T p.Lys460X  Lowe
 
1
 
+ + +  + + +  + + +  
03ls35 14 c.1402G>A p.Glu468Lys  Lowe
 
5
 
+  +  + + +   + +  
07ls20 14 c.1403A>G p.Glu468Gly  Lowe 5 +  + +  +    + +  
04ls11 14 c.1440-1441delCT p.Asp463AspfsX1  Lowe
 
0.1
 
+ + +   +    + +  
06ls19 i14 c.1467-3C>G Splicing defect  Lowe 7 +        +  +  
02ls50 15 c.1484C>A p.Pro495Leu 1.8 Lowe 3 +  +    +   +   
04ls05 15 c.1495G>C p.Asp499His  Lowe 5 +  + +  +       
06ls18 15 c.1507T>C p.Trp503Arg  Lowe 0.4 + + + +     +    
05ls21 16 c.1681_1682insGACT p.Phe561X  Lowe
 
2 + + + + + +   +  +  
00ls29 16 c.1692_1693insCCTT p.Leu565ProfsX11  Lowe
 
12
 
+ +  + + +       
07ls20 17 c.1773C>A p.Asn591Lys  Lowe 13 + + + + +    + +   
03ls23 17 c.1780C>T p.Gln594X  Lowe
 
0.9
 
+  + + + +     +  
04ls21 i17 c.1879+5G>A Splicing defect 0.3 Lowe
 
32
 
+    +/-        
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00ls23 18 c.1927_1928delGT p.Val643AsnfsX8 1.8 Lowe 0.3 + 
 
+
 
+
 
  
+ 
 
+
 
+
 
  
02ls35 18 c.2086G>T p.Glu696X  Lowe 20 + 
  
+
 
+
 
 
+   +  + 
07ls10 18 c.2092delC p.Pro681LeufsX66  Lowe
 
dead
 
+  +          
08ls011 19 c.2194dupC p.Leu732PfsX38  Lowe 1 + + + + + + +   +   
02ls11 19 c.2200delG p.Val734PhefsX8  Lowe 6 + 
 
+
 
  
+
 
      
08ls15 19 c.2224_2226delGTA p.Val742del  Lowe 10 + + + + + + + + + + + + 
98ls54 20 c.2269C>T p.Gln757X  Lowe 23 + 
 
+
 
+
 
+
 
+/-
 
+ +
 
+
 
+
 
+
 
 
05ls29 
09ls001 
20 
 
c.2311-2312insT 
 
p.Cys771LeufsX8 
 
 Lowe 
Lowe 
7 
2 
+ 
+ 
 + 
+ 
+ 
+ 
+ +  
+ 
  
+ 
+ 
+  
04ls17 21 c.2464C>T p.Arg822X  Lowe 2 + + + +   +   +   
05ls17 i21 c.2469+2T>G Splicing defect 0.3 Lowe
 
1 +  + + +/-  + +  +   
01ls19 i22 c.2581+1G>C Splicing defect  Lowe
 
1.5 + +           
03ls14 i22 c.2582-1G>A Splicing defect  Lowe
 
23 +    +  +   +   
06ls65 i22 c.2582-2A>G Splicing defect  Lowe
 
6 +  + + + + +  + +   
08ls03 23 c.2591_2595del6 p.Gln879_Thr880>HisfsX4  Lowe 28 +  + + + +  +  + +   
02ls08 23 c.2637_2638del p.Gln862HisfsX3  Lowe
 
12 +    +        
09ls013 23 c.2672T>G p.Leu891Arg  Lowe 10 +  + +   +  +    
06den06 3-4 del exon 3-4 Frameshift deletion  Dent 9 -  - - -  +   +  + 
00ls05 19-23 del exons 19-23 Frameshift deletion 1.8 Lowe 30 +  + + + +       
 
 
a Numbering was based on the cDNA sequence wih +1 corresponding to the A of the ATG initiation codon of translation in the reference sequence. 
b
 Expected consequences of the mutations with codon 1 corresponding to the ATG initiation codon of translation. 
c
 Enzyme activity measured in controls was N = 9.6 +/- 2.3 nanomoles PI(4,5)P2 hydrolyzed/min/mg 
d
 Age at the time of the molecular investigation 
e CC: congenital cataract, G: glaucoma, NH: neonatal hypotonia, DD: developmental delay, MR: mental retardation, FS: Fanconi syndrome, PT : proximal tubulopathy, 
  RF: renal failure, AA: amino-aciduria, LMWP: low molecular weight proteinuria; P: hypophosphatemia/hyperphosphaturia, Ca : hypercalciuria.  
  (+) sign present, (-) sign absent, ( ) sign not documented at the time of the last examination 
f Patients 02ls25 and 02ls26, and 10ls06 and 10ls017 are brothers 
g
 Variants c.1009C>T and c.1082G>T are on the same allele 
 
Table 1 : Novel mutations in the OCRL1 gene  
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 enzyme activity a 
(nanomol PI(4,5)P2 hydrolyzed mg-1 min-1) 
(+/- SEM) 
 
Patients with missense mutationsb 
    
   1.39 +/- 0.99  (n = 12) 
Patients with nonsense or frameshift mutationsb    1.54 +/- 0.63 (n = 11) 
Patients with no OCRL1 mutation identifiedc     9.43 +/- 1.47 (n = 12) 
Control individuals     9.62 +/- 2.31 (n=13) 
 
 
a  n value represent the number of independent patients tested, all measurements  
b
 19 patients were affected by Lowe syndrome, 4 presented with Dent-2 disease 
c
 these patients were adressed to the laboratory for molecular and biochemical investigations.  
  on the basis of suspicion of Lowe syndrome 
 
 
 
Table 2. PI(4,5)P2 phosphatase activity in patients with OCRL1 mutations 
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 OCRL1 / β ATPase a 
relative units (+/- SEM) 
 
Patients with nonsense or frameshift mutations 
 
Patients with missense mutations 
    
    0.05 +/- 0.02  (n = 11) 
   
    0.35 +/- 0.14  (n = 12) 
     
Control individuals     1.70 +/- 0.36  (n = 13) 
 
 
a  n value represent the number of independent patients tested 
 
 
Table 3. OCRL1 content in fibroblasts originating from patients with OCRL1 mutations 
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Patient 
ID 
Clinical 
diagnosisa 
Mutation Ageb PiP2ase 
activityc 
Ocular 
symptoms 
SNC 
symptomss 
Renal 
symptoms 
98ls18 
 
Lowe del exons 1-4 3  Congenital 
bilateral cataract 
Neonatal hypotonia, 
convulsions 
Fanconi syndrome 
06den06 
 
Dent del exon 3-4 14  None None LMW proteinuria, hypercalciuria 
02ls25d 
 
Lowe p.Ile274Thr 43  None Moderate mental retardation 
allowing an autonomous life 
Nephrotic syndrome, proteinuria, 
renal failure 
02ls26 d Lowe p.Ile274Thr 34  Congenital 
unilateral cataract 
Moderate mental retardation 
allowing an autonomous life 
Renal failure, proteinuria 
05den11 
 
Dent p.Ile274Thr 2  None Developmental delay Proximal tubulopathy, proteinuria, 
hypercalciuria 
06ls59 
 
Lowe p.Arg318Cys 24  Severe myopia Neonatal hypotonia, severe 
mental retardation 
Fanconi syndrome, proteinuria, 
hyperphophaturia, renal failure  
07den01 
 
Dent p.Arg318Cys 4  None None Tubular proteinuria, hypercalciuria 
98ls80 
 
Lowe p.Ala797Pro 57 2.9 Congenital 
bilateral cataract 
Moderate mental retardation 
and mild psychomotor 
troubles 
Fanconi syndrome 
04den05 
 
Dent p.Pro799Leu 21 0.8 None None 
 
LMW proteinuria, hypercalciuria, 
nephrocalcinosis, 
hyperphosphaturia, aminoaciduria 
06ls27 
 
Lowe p.Pro801Leu 1 1.6 Congenital 
bilateral cataract 
Neonatal hypotonia, 
moderate developmental 
delay, no psychomotor 
troubles 
Glomerular and tubular proteinuria 
a
 initial clinical diagnosis 
b
 age at the time of the molecular investigation 
c
 enzyme activity measured in controls was N = 9.6 +/- 2.3 nanomoles PI(4,5)P2 hydrolyzed/min/mg 
d
 patients 02ls25 and 02ls26 are brothers 
 
Table 4. Clinical expression of OCRL1 mutations in patients affected by Lowe syndrome or Dent disease 
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exon  
 Previous numberinga Corrected numberingb 
1 to -13 -169 to 39 
2 -12 to 68 40 to 119 
3 69 to 148 120 to 199 
4 149 to 187 200 to 238 
5 188 to 298 239 to 349 
6 299 to 388 350 to 439 
7 389 to 509 440 to 560 
8 510 to 670 561 to 722 
9 671 to 773 723 to 824 
10 774 to 888 825 to 939 
11 889 to 1004 940 to 1056 
12 1005 to 1193 1057 to 1244 
13 1194 to 1304 1245 to 1356 
14 1305 to 1415 1357 to 1466 
15 1416 to 1551 1467 to 1602 
16 1552 to 1662 1603 to 1713 
17 1663 to 1828 1714 to 1879 
18 1829 to 2064 1880 to 2115 
18a 2065 to 2088 2116 to 2140 
19 2089 to 2205 2141 to 2256 
20 2206 to 2290 2257 to 2341 
21 2291 to 2418 2342 to 2469 
22 2419 to 2530 2470 to 2581 
23 2531 to 4935 2582 to 4986 
 
a
 Previous numbering [Attree et al.,1992;  LSMD, 2010]  
b Conversion of previous numbering using the ATG start codon of exon 1 (+51 bp), bold 
  numbers correspond to exons for which boundaries have been corrected    
 
 
Supplementary table 1. Numbering of exon boundaries 
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 Exon 
Intron
 
Nucleotide 
changea 
 
 
Protein 
changeb 
 
 
Enzyme 
activity 
N = 1c 
Proteind Number  
of 
patientse 
Geographical 
originf 
Disease 
status 
References 
1 c.40-14A>G Splicing defect 0.17  1 France Dent-2 This paper 
4 c.217_218delTT p.Leu73AspfsX1   1 North-America Dent-2 Schimpton et al., 2009 
i4 c.238+4701A>G Splicing defect   1 UK Lowe This paper 
5 c.260_261delA p.Gln87ArgfsX88   2 Turkey Dent-2 Utsch et al., 2006 
5 c.303_310del8 p.Glu101GludelfsX27   1 Japan Dent-2 Sekine et al., 2007 
5 c.310_313delTGTT p.Cys104X 0.10 - 1 Germany Dent-2 Hoopes et al., 2005 
5 c.314T>A p.Leu105X   1 Italy Dent-2 Tosetto et al, 2009 
6 c.412_413insA T138 AsnfsX122   2 Germany Dent-2 Utsch et al., 2006 
i6 c.440-2A>G Splicing defect 0.11 - 1 Germany Dent-2 Hoopes et al., 2005 
7 c.487_488insAA p.K163KfsX2 0.09 - 1 Germany Dent-2 Hoopes et al., 2005 
7 c.497C>G p.Ser166X   1 North-America Dent-2 Schimpton et al., 2009 
7  p.Pro178HisfsX167   1 Italy Dent-2 Tosetto et al, 2009 
7 c.534_543del p.Pro178ProfsX3   1 North-America Dent-2 Schimpton et al., 2009 
7 c.560+1G>A p.Met187IlefsX1   1 North-America Dent-2 Schimpton et al., 2009 
i7 c.561-1G>A Splicing defect 0.10  1 North-America Lowe LSMD, 2010 
8 c.610delA p.Gln204ThrfsX45d   1 Italy Lowe
 
Addis et al., 2004 
8 c.632delT p.Val211AspfsX38   1 Spain Lowe
 
This paper 
8 c.643C>T p.Gln215X   1 North-America Lowe
 
LSMD, 2010 
8 c.646delT p.Ser216LeufsX39   1 ni Lowe LSMD, 2010 
8 c.688C>T p.Arg230X   1 Australia Lowe
 
This paper 
8 c.700_701delTA p.Tyr234CysfsX21   1 ni Lowe
 
LSMD, 2010 
8 c.701delA p.Tyr234LeufsX15   1 ni Lowe LSMD, 2010 
8 c.702T>G p.Tyr234X   1 Spain Lowe
 
This paper 
9 c.725T>C p.Phe242Ser 0.13 ++ 1 France Lowe
 
This paper 
9 c.740G>A p.Trp247X   1 ni Lowe
 
LSMD, 2010 
9 c.741G>T p.Trp247Cys   1 Italy Lowe
 
Addis et al., 2004 
9 c.767_768delCinsAGACTT p.Ser256_Gly257delinsfsX10   1 North-America Lowe
 
LSMD, 2010 
9 c.783G>C p.Trp261Cys   1 ni Lowe
 
LSMD, 2010 
9 c.814T>C p.Tyr272His   1 North-America Lowe
 
LSMD, 2010 
9 c.821T>C p.Ile274Thr   1 France Lowe
 
This paper 
9 c.821T>C p.Ile274Thr   2 Germany, France Dent-2 Utsch et al., 2006 ; this paper  
9 c.824G>C Splicing defect / p.Gly275Ala   1 France Lowe
 
Monnier et al., 2000 
i9 c.825-2A>G Splicing defect   1 French Lowe This paper 
10 c.827T>C p.Phe276Ser 0.05 +++ 1 Morocco Lowe
 
Chabaa et al., 2006 
10 c.830A>G p.Gln277Arg   1 India Lowe
 
Sehti et al., 2008 
10 c.860T>C p.Phe287Ser   1 Italy Dent-2 Tosetto et al, 2009 
10 c.870delA p.Glu290AspfsX2   1 ni Lowe
 
LSMD, 2010 
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10 c.874delG p.Val292X 0,05 - 1 North-America Lowe
 
Lin et al., 1997 
10 c.883C>T p.Gln295X   1 North-America Lowe
 
Lin et al., 1997 
10 c.890G>A p.Trp297X   1 Germany Lowe
 
LSMD, 2010 
10 c.904G>T p.Glu302X   1 India Lowe
 
Sehti et al., 2008 
10 c.907_908delAG p.Arg303ArgfsX9   1 France Lowe
 
Monnier et al., 2000 
i10 
 
c.940-11G>A 
 
Splicing defect 
 
0,13-0.17 - 5 China, France 
Norway, Japan 
Lowe Chou et al., 2005 ; this paper  
i10 c.940-1G>A Splicing defect   1 ni Lowe Lin et al., 1998 
11 
 
c.952C>T 
 
p.Arg318Cys 
 
0.16-0.18 +++ 3 Germany, France 
Japan 
Dent-2 Hoopes et al., 2005 ; Sekine et al., 2007 ; 
this paper 
11 c.952C>T p.Arg318Cys   1 France Lowe This paper                                       
11 c.953G>A p.Arg318His   1 North-America Dent-2 Schimpton et al., 2009 
11 c.962G>A p.Gly321Glu   1 North-America Dent-2 Schimpton et al., 2009 
11 c.975-976insA p.Leu325LeufsX14   1 France Lowe Satre et al., 1999 
11 c.982G>C p.Ala328Pro   1 ni Lowe Lin et al., 1998 
11 c.1000C>T p.Arg334X   3 Spain, France Lowe Satre et al., 1999 ; Monnier et al., 2000  
11 c.1001G>C p.Arg334Pro   1 ni Lowe
 
LSMD, 2010 
11 c.1005C>G p.Tyr335X   1 France Lowe This paper 
11 c.1009C>T  p.Arg337Cys  0.15  1 France Lowe This paper 
12 c.1060A>C p.Asn354His   1 France Dent-2 This paper 
12 c.1064_1014delAA p.Lys355ArgdelfsX29   1 ni Lowe
 
LSMD, 2010 
12 c.1070G>A p.Gly357Glu   2 France Lowe
 
Monnier et al., 2000 
12 c.1082G>T p.Arg361Ile   1 France Lowe This paper 
12 
 
c.1099-1101delACC 
 
p.Thr367del 
 
0.01 + 2 North-America 
Spain 
Lowe
 
Lin et al., 1997 ; Satre et al., 1999 
12 c.1115T>G p.Val372Gly   1 France Lowe
 
This paper 
12 c.1117A>T p.Asn373Tyr 0.15 ++ 1 France Lowe
 
This paper 
12 c.1121C>T p.Ser374Phe   1 France Lowe This paper 
12 c.1123C>T p.His375Tyr 0.0 + 1 North-America Lowe
 
Kubota et al., 1998 
12 c.1161_1162insT p.Gln388SerfsX4   1 ni Lowe
 
LSMD, 2010 
12 
 
c.1162C>T 
 
p.Gln388X 
 
0.12 - 3 North-America 
Japan, Germany 
Lowe
 
Lin et al., 1997 ; Kubota et al., 1998 ; 
Röschinger et al., 2000 
12 c.1222C>T p.Gln408X   2 Japan Lowe Kubota et al., 1998 
12 c.1234_1235insT p.Met412IlefsX4   1 India Lowe
 
Sehti et al., 2008 
12 c.1241A>G p.His414Arg   2 Kosovo Lowe This paper 
i12 c.1244+1G>C Splicing defect   1 Italy Lowe
 
Addis et al., 2004 
13 c.1262G>A p.Gly421Glu 
0.05-0.19 + 4 Canada, 
Switzerland 
Lowe
 
Monnier et al., 2000 ; this paper 
13 c.1264G>A p.Asp422Asn   1 ni Lowe
 
LSMD, 2010 
13 c.1270A>G p.Asn424Asp   1 France Lowe
 
Monnier et al., 2000 
13 c.1309delA p.Ser437ValfsX12   1  Lowe
 
LSMD, 2010 
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13 c.1341_1342delCT pLeu448GlufsX17   1 France Lowe This paper 
13 c.1328delA p.Asp443AlafsX6   1 France Lowe
 
Monnier et al., 2000 
13 c.1351G>A p.Asp451Asn   1 France Lowe
 
This paper 
13 c.1352A>G p.Asp451Gly 0.02 + 1 North-America Lowe
 
Lin et al., 1997 
13 c.1355delA p.Gln452ArgfsX2   1 Australia Lowe
 
This paper 
14 c.1369C>G p.Arg457Gly 0,06 +/- 1 Canada Lowe
 
This paper 
14 c.1378A>T p.Lys460X   1 Spain Lowe
 
This paper 
14 c.1387T>C p.Phe463Ser   1 North-America Lowe
 
Lin et al., 1997 
14 c.1402G>A p.Glu468Lys   1 France Lowe
 
This paper 
14 c.1403A>G p.Glu468Gly  ++ 1 France Lowe This paper 
14 c.1424G>A p.Pro475His   1 China Lowe
 
Chou et al., 2005  
14 c.1431T>G P.Tyr477X   2 Italy Lowe
 
Addis et al., 2004 
14 c.1432_1437del6 p.Lys479_Tyr480del   1 Germany Lowe
 
Röschinger et al., 2000 
14 c.1436A>G p.Tyr479Cys 0.13 ++ 1 Germany Dent-2 Hoopes et al., 2005 
14 c.1440-1441delCT p.Asp480AspfsX1   1 Australia Lowe
 
This paper 
14 c.1466G>A Splicing defect / p.Ser489Asn    1 France Lowe
 
Monnier et al., 2000 
i14 c.1467-3C>G Splicing mutation   1 UK Lowe
 
This paper 
15 c.1477C>T p.Arg493Trp   2 Germany, Japan Dent-2 Utsch et al., 2006 ; Sekine et al., 2007 
15 c.1484C>A p.Pro495Leu 0,12 + 1 Belgium Lowe
 
This paper 
15 c.1489T>G p.Trp497Gly   1 ni Lowe
 
Schneider et al., 2001 
15 c.1490G>A p.Trp497X   1 ni Lowe
 
LSMD, 2010 
15 c.1493G>A p.Cys498Tyr   2 France Lowe
 
Monnier et al., 2000 
15 c.1495G>C p.Asp499His   1 Norway Lowe
 
This paper 
15 c.1495-1496ins21 p.Asp499delinsGRVPATCY   1 ni Lowe Böckenhauer et al., 2008 
15 c.1498C>G p.Arg500Gly   2 France, ni Lowe
 
Satre et al., 1999 
15 
 
c.1498C>T 
 
p.Arg500X 
 
  5 Serbia, France, 
India 
Lowe
 
Monnier et al., 2000 ; this paper  
15 
 
 
c.1499G>A 
 
 
p.Arg500Gln 
 
 
0.1 + 9 North-America 
Japan, Germany, 
France 
Lowe
 
Lin et al., 1997 ; Kawano et al., 1998 ; 
Röschinger et al., 2000 ; LSMD, 2010 ; 
this paper 
15 c.1507T>C p.Trp503Arg   1 France Lowe
 
This paper 
15 c.1517delC p.Thr506LysfsX13   1 Basque country Lowe
 
Monnier et al., 2000 
15 c.1518delA pThr506ThrfsX13 0.08 - 1 North-America Lowe
 
Lin et al., 1997 
15 c.1523T>A p.Val508Asp   1 North-America Lowe
 
Lin et al., 1998 
15 c.1538A>G p.Tyr513Cys 0,10 ++++ 1 North-America Lowe
 
Lin et al., 1998 
15 c.1566C>G p.Ser522Arg   1 Japan Lowe
 
Kubota et al., 1998 
15 c.1567G>A p.Asp523Asn   1 Italy Dent-2 Tosetto et al, 2009 
15 c.1568A>G p.Asp523Gly    1 ni Lowe
 
LSMD, 2010 
15 c.1571A>G p.His524Arg 0.03 ++ 1 North-America Lowe
 
Lin et al., 1997 
15 c.1572C>G p.His524Gln 0.1 - 1 Japan Lowe
 
Kawano et al., 1998 
15 c.1576C>A p.Pro526Thr     1 ni Lowe
 
LSMD, 2010 
Page 43 of 46
John Wiley & Sons, Inc.
Human Mutation
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
15 c.1577C>T p.Pro526Leu   1 Germany Lowe
 
Röschinger et al., 2000 
15 c.1580T>A p.Val527Asp   1 Italy Lowe
 
Addis et al., 2004 
15 c.1598T>G p.Ile533Ser deficient  1 ni Lowe
 
LSMD, 2010 
i15 c.1602+1G>A Splicing defect 0.17 + 2 Israel, France Lowe
 
Monnier et al., 2000 ; this paper   
i15 c.1603-2A>G Splicing defect   1 ni Lowe Böckenhauer et al., 2008 
16 c.1621C>T p.Arg541X   5 France, India, ni Lowe
 
LSMD, 2010 ; this paper 
16 c.1680_1683delCTTC p.Asp560AspfsX4   1 France Lowe
 
Satre et al., 1999 
16 c.1681_1682insGACT p.Phe561X   1 Spain Lowe
 
This paper 
16 c.1692_1693insCCTT p.Leu564ProfsX11   1 Morocco Lowe
 
This paper 
16 c.16494_1695insCCTT p.Leu565PhefsX11   4 ni Lowe
 
Addis et al., 2004 
16 c.1709_1710insG p.Arg570ArgfsX6   1 France Lowe
 
Monnier et al., 2000 
i16 1714-2A>G Splicing defect   2 Belgium, ni Lowe
 
LSMD, 2010 ; this paper 
17 c.1722-1723insT p.Glu575X   1 Germany Lowe Röschinger et al., 2000 
17 c.1723G>T p.Glu575X   1 Lebanon Lowe
 
Satre et al., 1999 
17 c.1730T>A Splicing defect / p.Val577Glu   1 Italy Lowe
 
Addis et al., 2004 
17 c.1737delT p.Phe579PhefsX64   1 ni Lowe
 
LSMD, 2010 
17 c.1751_1752insG p.Glu585LysfsX21   1 France Lowe
 
Monnier et al., 2000 
17 c.1753_1755delGAG p.Glu585del   1 France Lowe
 
Monnier et al., 2000 
17 c.1769delG P.Ser590ThrfsX53   1 ni Lowe
 
LSMD, 2010 
17 c.1773C>A p.Asn591Lys   1 Turkey Lowe
 
This paper 
17 c.1777delG p.Gly593AspfsX51   1 Spain Lowe
 
Satre et al., 1999 
17 c.1780C>T p.Gln594X   1 Arabia Lowe
 
This paper 
17 1822_1834del13nt p.Ser608_Lys312>SerfsX32   1 France Lowe
 
Monnier et al., 2000 
17 1830C>G p.Tyr613X   1 ni Lowe
 
LSMD, 2010 
i17 c.1879+5G>A Splicing defect 0.03 - 1 France Lowe
 
This paper 
i17 c.1880-5_1880-21del16 p.Asn627fsX16   1 Italy Lowe
 
Addis et al., 2004 
18 c.1901T>C p.Leu634Pro   1 The Netherlands Lowe Böckenhauer et al., 2008 
18 c.1923-1924delT p.Ser642CysfsX4   1 ni Lowe Böckenhauer et al., 2008 
18 c.1925_1926delCT p.Ser642CysfsX9   1 North-America Lowe
 
Lin et al., 1997 
18 c.1927_1928delGT p.Val643AsnfsX9 0.21 +/- 1 France Lowe
 
This paper 
18 c.1987C>T p.Arg663X 0.04 - 5 North-America Finland, France 
Lowe
 
Lin et al., 1997 ; Monnier et al., 2000 ; 
LSMD, 2010   
18 c.2002T>G p.Phe668Val   1 France Lowe
 
Swan et al., 2010 
18 c.2037T>G p.Cys679Trp   1 Italy Lowe McCrea et al., 2008 
18 c.2060T>C p.Leu687Pro   1 ni Lowe
 
LSMD, 2010 
18 c.2071A>T p.Lys691X   2 ni Lowe Böckenhauer et al., 2008 
18 c.2071delA p.Lys691LysfsX13   1 France Lowe
 
Monnier et al., 2000 
18 c.2083C>T p.Arg695X   5 North-America Kuweit, France 
Lowe
 
Lin et al., 1998 ; Monnier et al., 2000 ; 
Addis et al., 2004   
18 c.2086G>T p.Glu696X   1 Belgium Lowe
 
This paper 
18 c.2092delC p.Pro698LeufsX66   1 Israel Lowe
 
This paper 
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19 c.2194dupC p.Leu732ProfsX38   1 UK Lowe This paper 
19 c.2200delG p.Val734PhefsX8   1 Belgium Lowe
 
This paper 
19 c.2203_2204insA p.Pro735HisfsX35   1 North-America Lowe
 
Lin et al., 1998 
19 c.2212G>C p.Glu737Asp   1 Italy Dent-2 Tosetto et al, 2009 
19 c.2224_2226delGTA p.Val742del   1 Cuba Lowe This paper 
19 c.2244C>G p.Tyr748X   1 ni Lowe
 
LSMD, 2010 
i19 c.2256+1G>A Splicing defect   1 Germany Lowe Keilhauer et al., 2007 
20 c.2265delG p.Leu755LeufsX70   1 Belgium Lowe
 
Monnier et al., 2000 
20 c.2269C>T p.Gln757X   1 France Lowe
 
This paper 
20 c.2269delC p.Gln757ArgfsX68   1 ni Lowe
 
LSMD, 2010 
20 c.2297delA p.Gln766fsX58   1 Italy Lowe
 
Addis et al., 2004 
20 c.2303T>A p.Ile768Asn   1 France Lowe
 
Monnier et al., 2000 
20 c.2311-2312insT p.Cys771LeufsX8   2 France, Mali Lowe
 
This paper 
21 c.2341+1_del6 Splicing defect   1 ni Lowe Böckenhauer et al., 2008 
21 
 
c.2360_2361delTG 
 
p.Val787GlyfsX2 
 
0.10-0.16 - 4 North-America, 
India 
Lowe
 
Lin et al., 1997 ; Lin et al., 1998 ; this 
paper  
21 c.2389G>C p.Ala797Pro 0.39 ++ 1 France Lowe
 
Monnier et al., 2000 
21 c.2396C>T p.Pro799Leu 0.09 ++ 1 France Dent-2 Swan et al., 2010 
21 c.2402C>T p.Pro801Leu 0.22  1 France Lowe
 
Swan et al., 2010 
21 c.2415C>G p.Tyr805X   2 France Lowe
 
Monnier et al., 2000 ; this paper  
21 c.2416G>T p.Glu806X   1 ni Lowe
 
LSMD, 2010 
21 c.2428C>T p.Arg810X 0.27  5 UK, India Lowe
 
Monnier et al., 2000 ; this paper 
21 c.2433T>A p.Cys811X   1 ni Lowe
 
LSMD, 2010 
21 
 
c.2464C>T 
 
p.Arg822X 
 
  3 Germany 
Lebanon, ni 
Lowe
 
This paper 
21 c.2467C>T p.Gln823X 0,05 - 1 North-America Lowe
 
Lin et al., 1998 
i21 c.2469+2T>G Splicing defect 0.03  1 French Lowe
 
This paper 
i21 c.2469+2_6delinsA Splicing defect   1 ni Lowe
 
LSMD, 2010 
22 c.2470_2481del12 p.Val824_Gln27del   1 North-America Lowe
 
Leahey et al., 1993 
22 c.2515_2516insC p.Leu839SerfsX12   1 ni Lowe
 
LSMD, 2010 
22 c.2530C>T p.Arg844X   4 North-America Lowe
 
Leahey et al., 1993 
22 c.2533G>T p.Glu845X   1 France Lowe
 
Monnier et al., 2000 
22 c.2550_2551insT p.Glu851X 0.07 + 1 North-America Lowe
 
Gropman et al., 2000 
22 c.2553_7 del p.Glu851GlufsX1   1 ni Lowe Böckenhauer et al., 2008 
22 
 
c.2581G>A 
 
Splicing defect, p.Ala861Thr 
 
0.14 - 10 Japan, Brasil, 
Italy Belgium, 
France, India 
Lowe Kawano et al., 1998 ; Monnier et al., 
2000 ; Addis et al., 2004 ; Böckenhauer et 
al., 2008 ; LSMD, 2010 ; this paper  
i22 c.2581+1G>C Splicing defect   1 Spain Lowe
 
This paper 
i22 c.2581+4A>G Splicing defect   1 ni Lowe
 
LSMD, 2010 
i22 c.2582-1G>A Splicing defect   1 Spain Lowe
 
This paper 
i22 c.2582-2A>G Splicing defect   1 India Lowe
 
Sehti et al., 2008 
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23 c.2591_2595delTCACT p.Phe864X   1 France Lowe This paper 
23 c.2622delC p.Asn874AsnfsX34 0.29  2 France, ni Lowe
 
Satre et al., 1999 ; LSMD, 2010 
23 c.2637_2638delGA p.Gln879_Thr880>HisfsX4   1 Grece Lowe
 
This paper  
23 c.2642_2643insC p.Pro881ProfsX2   1 ni Lowe
 
LSMD, 2010 
23 c.2672T>G p.Leu891Arg   1 Maroco Lowe This paper   
1-3 del exons 1-3 Genomic deletion, frameshift   1 France Lowe
 
Monnier et al., 2000 
1-4 del exons 1-4 Genomic deletion, frameshift   1 France Lowe
 
Monnier et al., 2000 
3-4 del exon 3-4 Genomic deletion, frameshift   1 France Dent-2 This paper 
5-8 del exons 5-8 Genomic deletion, frameshift   1 France Lowe
 
Monnier et al., 2000 
6-12 del exons 6-12 Genomic deletion, frameshift   2 North-America Lowe
 
LSMD, 2010 
8-12 del exons 8-12 Genomic deletion   1 Belgium Lowe
 
Monnier et al., 2000 
14 del exon 14 Genomic deletion, frameshift 0,10 - 1 North-America Lowe
 
Lin et al., 1997 
19-23 del exons 19-23 Genomic deletion, frameshift 0,19  1 Canada Lowe
 
This paper 
1-23 del OCRL Genomic deletion,    2 Australia, Italy Lowe
 
Peverall et al., 2000 ; Addis et al., 2007 
 
Supplementary Table  S3 : Reported mutations in the OCRL1 gene 
 
a Numbering was based on the cDNA sequence (#NM_000276) wih +1 corresponding to the A of the ATG initiation codon of translation in the reference sequence.  
b
 Expected consequences of the mutations with codon 1 corresponding to the ATG initiation codon of translation. 
c
 The enzyme activities were normalized versus the normal activity values indicated by the different authors with 1 being the normal average value measured in controls. 
  When 2 or more patients have been tested for enzyme activity, extreme values are indicated. 
d
 The amount of OCRL1 present in patients' fibroblasts was  estimated by western blot with ++++ indicating a normal amount  and - a complete absence of the protein.  
e
 Total number of independent patients reported with the specific mutation.  
f
 ni: geographical origin of the patient not indicated 
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